Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Landa

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcomaMark A Dickson, William D Tap, Mary Louise Keohan, et al.
Cancer Immunology Research|May 23, 2019
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential SynergyEric L Smith, Sham Mailankody, Mette Staehr, et al.
The Oncologist|October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue SarcomasRodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated AnalysisEric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2020
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I StudyKaren A Autio, Christopher A Klebanoff, David Schaer, et al.
The New England Journal of Medicine|September 28, 2022
GPRC5D-Targeted CAR T Cells for MyelomaSham Mailankody, Sean M Devlin, Jonathan Landa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2023
Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated LiposarcomaCaroline E Gleason, Mark A Dickson, Mary E Klein Dooley, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcomaMark A Dickson, William D Tap, Mary Louise Keohan, et al.
Cancer Immunology Research|May 23, 2019
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential SynergyEric L Smith, Sham Mailankody, Mette Staehr, et al.
The Oncologist|October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue SarcomasRodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated AnalysisEric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2020
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I StudyKaren A Autio, Christopher A Klebanoff, David Schaer, et al.
The New England Journal of Medicine|September 28, 2022
GPRC5D-Targeted CAR T Cells for MyelomaSham Mailankody, Sean M Devlin, Jonathan Landa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2023
Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated LiposarcomaCaroline E Gleason, Mark A Dickson, Mary E Klein Dooley, et al.
Pageof 3